Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...
A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...
There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...
Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published ...
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...
A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...
Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...
In a small trial, 8 of 16 patients responded well to the mRNA vaccine The vaccine is personalized, based on each patient’s ...
The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results